{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:37:50Z","timestamp":1784986670138,"version":"3.55.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Dyspnoea often occurs in patients with acute coronary syndrome (ACS) treated with ticagrelor compared with other anti-platelet agents and is a cause of drug discontinuation. We aimed to explore the contribution of central apnoeas (CA) and chemoreflex sensitization to ticagrelor-related dyspnoea in patients with ACS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Sixty consecutive patients with ACS, preserved left ventricular ejection fraction, and no history of obstructive sleep apnoea, treated either with ticagrelor 90\u2009mg b.i.d. (n\u2009=\u200930) or prasugrel 10\u2009mg o.d. (n\u2009=\u200930) were consecutively enrolled. One week after ACS, all patients underwent two-dimensional Doppler echocardiography, pulmonary static\/dynamic testing, carbon monoxide diffusion capacity assessment, 24-h cardiorespiratory monitoring for hypopnoea\u2013apnoea detection, and evaluation of the chemosensitivity to hypercapnia by rebreathing technique. No differences were found in baseline demographic and clinical characteristics, echocardiographic, and pulmonary data between the two groups. Patients on ticagrelor, when compared with those on prasugrel, reported more frequently dyspnoea (43.3% vs. 6.7%, P\u2009=\u20090.001; severe dyspnoea 23.3% vs. 0%, P\u2009=\u20090.005), and showed higher apnoea\u2013hypopnoea index (AHI) and central apnoea index (CAI) during the day, the night and the entire 24-h period (all P\u2009&amp;lt;\u20090.001). Similarly, they showed a higher chemosensitivity to hypercapnia (P\u2009=\u20090.001). Among patients treated with ticagrelor, those referring dyspnoea had the highest AHI, CAI, and chemosensitivity to hypercapnia (all P\u2009&amp;lt;\u20090.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Central apnoeas are a likely mechanism of dyspnoea and should be screened for in patients treated with ticagrelor. A drug-related sensitization of the chemoreflex may be the cause of ventilatory instability and breathlessness in this setting.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaa089","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T19:10:51Z","timestamp":1594235451000},"page":"180-188","source":"Crossref","is-referenced-by-count":21,"title":["Central apnoeas and ticagrelor-related dyspnoea in patients with acute coronary syndrome"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9314-2005","authenticated-orcid":false,"given":"Alberto","family":"Giannoni","sequence":"first","affiliation":[{"name":"Cardiology and Cardiovascular Medicine Department, Fondazione Toscana G. Monasterio, via Giuseppe Moruzzi 1, 56124 Pisa, Italy"},{"name":"Institute of Life Sciences, Scuola Superiore Sant\u2019Anna, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8464-4230","authenticated-orcid":false,"given":"Chiara","family":"Borrelli","sequence":"additional","affiliation":[{"name":"Institute of Life Sciences, Scuola Superiore Sant\u2019Anna, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7453-3748","authenticated-orcid":false,"given":"Francesco","family":"Gentile","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiovascular Medicine Department, Fondazione Toscana G. Monasterio, via Giuseppe Moruzzi 1, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Mirizzi","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiovascular Medicine Department, Fondazione Toscana G. Monasterio, via Giuseppe Moruzzi 1, 56124 Pisa, Italy"},{"name":"Institute of Life Sciences, Scuola Superiore Sant\u2019Anna, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Coceani","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiovascular Medicine Department, Fondazione Toscana G. Monasterio, via Giuseppe Moruzzi 1, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Paradossi","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiac Surgery Department, Fondazione Toscana G. Monasterio, Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiovascular Medicine Department, Fondazione Toscana G. Monasterio, via Giuseppe Moruzzi 1, 56124 Pisa, Italy"},{"name":"Institute of Life Sciences, Scuola Superiore Sant\u2019Anna, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bramanti","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiovascular Medicine Department, Fondazione Toscana G. Monasterio, via Giuseppe Moruzzi 1, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Iudice","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiovascular Medicine Department, Fondazione Toscana G. Monasterio, via Giuseppe Moruzzi 1, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiovascular Medicine Department, Fondazione Toscana G. Monasterio, via Giuseppe Moruzzi 1, 56124 Pisa, Italy"},{"name":"Institute of Life Sciences, Scuola Superiore Sant\u2019Anna, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0723-4753","authenticated-orcid":false,"given":"Claudio","family":"Passino","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiovascular Medicine Department, Fondazione Toscana G. Monasterio, via Giuseppe Moruzzi 1, 56124 Pisa, Italy"},{"name":"Institute of Life Sciences, Scuola Superiore Sant\u2019Anna, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"2021052315102652300_pvaa089-B1","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2021052315102652300_pvaa089-B2","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"2021052315102652300_pvaa089-B3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2010.01.062","article-title":"Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET\/OFFSET study","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2021052315102652300_pvaa089-B4","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.jacc.2019.03.470","article-title":"Premature ticagrelor discontinuation in secondary prevention of atherosclerotic CVD: JACC review topic of the week","volume":"73","author":"Arora","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2021052315102652300_pvaa089-B5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/14656566.2017.1421634","article-title":"Ticagrelor in modern cardiology \u2013 an up-to-date review of most important aspects of ticagrelor pharmacotherapy","volume":"19","author":"Danielak","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"2021052315102652300_pvaa089-B6","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"2021052315102652300_pvaa089-B7","doi-asserted-by":"crossref","first-page":"e006132","DOI":"10.1161\/CIRCINTERVENTIONS.117.006132","article-title":"Frequency, reasons, and impact of premature ticagrelor discontinuation in patients undergoing coronary revascularization in routine clinical practice: results from the Bern Percutaneous Coronary Intervention Registry","volume":"11","author":"Zanchin","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"2021052315102652300_pvaa089-B8","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMc1601662","article-title":"Cheyne-stokes respiration, chemoreflex, and ticagrelor-related dyspnea","volume":"375","author":"Giannoni","year":"2016","journal-title":"N Engl J Med"},{"key":"2021052315102652300_pvaa089-B9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.sleep.2017.09.033","article-title":"Dyspnea or Cheyne-stokes respiration associated with ticagrelor?","volume":"43","author":"Lamberts","year":"2018","journal-title":"Sleep Med"},{"key":"2021052315102652300_pvaa089-B10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/FJC.0000000000000518","article-title":"Reversal of ticagrelor-induced arrhythmias and cheyne-stokes respiration with aminophylline infusion","volume":"70","author":"Conte","year":"2017","journal-title":"J Cardiovasc Pharmacol"},{"key":"2021052315102652300_pvaa089-B11","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.jacc.2018.03.447","article-title":"Ticagrelor and central sleep apnea","volume":"71","author":"Revol","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2021052315102652300_pvaa089-B12","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jacc.2017.07.740","article-title":"Prognostic significance of central apneas throughout a 24-hour period in patients with heart failure","volume":"70","author":"Emdin","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2021052315102652300_pvaa089-B13","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1016\/j.jacc.2020.04.033","article-title":"Upright Cheyne-stokes respiration in patients with heart failure","volume":"75","author":"Giannoni","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2021052315102652300_pvaa089-B14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1042\/CS20070292","article-title":"Clinical significance of chemosensitivity in chronic heart failure: influence on neurohormonal derangement, Cheyne-stokes respiration and arrhythmias","volume":"114","author":"Giannoni","year":"2008","journal-title":"Clin Sci (Lond)"},{"key":"2021052315102652300_pvaa089-B15","doi-asserted-by":"crossref","first-page":"e012419","DOI":"10.1161\/JAHA.119.012419","article-title":"Contribution of the lung to the genesis of Cheyne-stokes respiration in heart failure: plant gain beyond chemoreflex gain and circulation time","volume":"8","author":"Giannoni","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2021052315102652300_pvaa089-B16","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Eng J Med"},{"key":"2021052315102652300_pvaa089-B17","first-page":"825","article-title":"The perception of breathlessness in asthma","volume":"126","author":"Burdon","year":"1982","journal-title":"Am Rev Respir Dis"},{"key":"2021052315102652300_pvaa089-B18","doi-asserted-by":"crossref","first-page":"479","DOI":"10.5664\/jcsm.6506","article-title":"Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine Clinical Practice Guideline","volume":"13","author":"Kapur","year":"2017","journal-title":"Clin Sleep Med"},{"key":"2021052315102652300_pvaa089-B19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0034-5687(00)00095-5","article-title":"A model of the chemoreflex control of breathing in humans: model parameters measurement","volume":"120","author":"Duffin","year":"2000","journal-title":"Respir Physiol"},{"key":"2021052315102652300_pvaa089-B20","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N Engl J Med"},{"key":"2021052315102652300_pvaa089-B21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12872-020-01419-y","article-title":"The risk of dyspnea in patients treated with third-generation P2Y12 inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"2021052315102652300_pvaa089-B22","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.amjcard.2011.07.015","article-title":"Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patients Outcomes (PLATO) pulmonary function substudy)","volume":"108","author":"Storey","year":"2011","journal-title":"Am J Cardiol"},{"key":"2021052315102652300_pvaa089-B23","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J"},{"key":"2021052315102652300_pvaa089-B24","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1160\/TH12-08-0547","article-title":"Why does ticagrelor induce dyspnea?","volume":"108","author":"Cattaneo","year":"2012","journal-title":"Thromb Haemost"},{"key":"2021052315102652300_pvaa089-B25","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCULATIONAHA.118.034489","article-title":"Adenosine and ticagrelor plasma levels in patients with and without ticagrelor-related dyspnea","volume":"138","author":"Ortega-Paz","year":"2018","journal-title":"Circulation"},{"key":"2021052315102652300_pvaa089-B26","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/CIRCULATIONAHA.118.034790","article-title":"Study of two dose regimens of ticagrelor compared with clopidogrel in patients undergoing percutaneous coronary intervention for stable coronary artery disease (STEEL-PCI)","volume":"138","author":"Orme","year":"2018","journal-title":"Circulation"},{"key":"2021052315102652300_pvaa089-B27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/1074248411410883","article-title":"Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hypermeia responses in a canine model","volume":"17","author":"Van Giezen","year":"2012","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2021052315102652300_pvaa089-B28","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jcin.2020.02.009","article-title":"No significant relationship between ticagrelor and sleep apnea in large, randomized, blinded trials","volume":"13","author":"Sabatine","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"2021052315102652300_pvaa089-B29","doi-asserted-by":"crossref","first-page":"180114","DOI":"10.1183\/16000617.0114-2018","article-title":"Obstructive sleep apnoea in acute coronary syndrome","volume":"28","author":"Randerath","year":"2019","journal-title":"Eur Respir Rev"},{"key":"2021052315102652300_pvaa089-B30","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamainternmed.2019.6447","article-title":"Association of ticagrelor vs clopidogrel with major adverse coronary events in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"180","author":"Turgeon","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2021052315102652300_pvaa089-B31","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11302-012-9303-x","article-title":"P2Y12 receptors in platelets and other hematopoietic and non-hematopoietic cells","volume":"8","author":"Gachet","year":"2012","journal-title":"Purinergic Signal"},{"key":"2021052315102652300_pvaa089-B32","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1126\/science.1190721","article-title":"Astrocytes control breathing through pH-dependent release of ATP","volume":"329","author":"Gourine","year":"2010","journal-title":"Science"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaa089\/33717160\/pvaa089.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/3\/180\/38114284\/pvaa089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/3\/180\/38114284\/pvaa089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T15:10:51Z","timestamp":1621782651000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/7\/3\/180\/5871923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,7,15]]},"published-print":{"date-parts":[[2021,5,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa089","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2020,7,15]]}}}